By Oct. 1, at least 2 million seniors will have received alarming notices: Their health plans — which they get through Medicare Advantage, the version of Medicare run by private health insurance companies — will disappear at the end of the year.

23 Oct 2026

Better engineering of hospital handbasins could prevent superbug outbreaks

Handbasins help prevent infections in hospitals but new research from Flinders University warns that contaminated basins in healthcare might put patients at risk and have implications in outbreaks of superbugs.

23 Oct 2026

BioUK Awards 2026 celebrate outstanding achievement and breakthrough innovations from across the life sciences

BioUK, the not-for-profit membership organization focused on catalyzing success in UK life sciences, today announced the winners of the 18th annual BioUK Awards following a ceremony hosted at the Royal Lancaster Hotel, London.

From BioUK 23 Oct 2026

Standardized protocol enables safer kidney biopsies in high-risk patients

Results from a prospective study reveal that with standardized precautions, even high-risk patients may safely undergo a kidney biopsy, a cornerstone of kidney diagnostics that is often perceived as dangerous in certain vulnerable patient populations.

22 Oct 2026

Psilocybin reshapes brain connections through distinct cellular pathways

A new study led by researchers at the University of California, Santa Cruz, reveals how psilocybin, the psychoactive compound in "magic mushrooms," reshapes neural connections in the brain.

22 Oct 2026

Study challenges concerns linking ADHD medication to self-harm risk

The risk of self-harm amongst people with attention deficit hyperactivity disorder (ADHD) is highest before people start ADHD medication, rather than after treatment begins, according to new research led by Aston University.

22 Oct 2026

Scientists studied one million immune cells and found clues to future disease risk

Researchers developed a single-cell atlas of one million human neutrophils, identifying distinct immune cell populations and gene-expression patterns across tissues, infections, cancer, and other health conditions. Certain neutrophil signatures were associated with metabolic dysfunction, cancer outcomes, and mortality, while higher routine neutrophil counts, even within the normal range, were linked to an increased risk of chronic disease.

22 Oct 2026

Clinical trial establishes effective HIV dosing regimen for full-term newborns

An international study conducted through the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network including researchers at the University of California San Diego helped inform the U.S. Food and Drug Administration's (FDA) recent approval of dolutegravir, a second-generation integrase inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in newborns from birth.

22 Oct 2026

Baylor Scott & White Health and Thrive Global partner to enhance customer well-being

Baylor Scott & White Health and Thrive Global today announce a strategic collaboration aimed at helping customers better manage their well-being every day.

22 Oct 2026

Gaining too much weight during pregnancy raises complication risks

A new study of more than one million births led by McMaster University researchers has found that gaining too much weight during pregnancy, regardless of a person's starting weight, is linked to a higher risk of life-threatening maternal complications.

22 Oct 2026

Large-scale meteorological patterns linked to Ebola virus outbreaks

A study led by the University of Malaga has shown that outbreaks of Ebola virus do not occur randomly over time; rather, their appearance is linked to specific large-scale meteorological patterns, even with oscillations occurring in regions thousands of miles away from Central Africa, where they are currently suffering from an epidemic of this disease, which can be fatal.

22 Oct 2026

ESMO updates precision oncology framework to improve targeted therapies

ESMO has published version 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), a major update to the internationally recognized precision oncology framework that helps oncologists assess the clinical relevance of molecular alterations and match patients with the most appropriate targeted therapies.

22 Oct 2026

Young cancer survivors face critical gaps in follow-up care

Young adult cancer survivors face gaps in follow-up care caused by factors including geographic mobility and insurance changes, according to an analysis by UTHealth Houston researchers.

22 Oct 2026

Australian study highlights delayed diagnosis in postpartum psychosis care

Women with postpartum psychosis are making repeated pleas for help before receiving a diagnosis, with the first Australian study of their help-seeking experiences finding many contacted health services an average of seven times before getting the care they needed.

22 Oct 2026

Zylidac Bio and Prolific Machines partner to scale Prolific’s next-generation biologics manufacturing platform to GMP production

Zylidac Bio, a fully integrated biologics CDMO within the Zydus Lifesciences Limited (Zydus) group, and Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced a partnership to scale Prolific's platform from early development through GMP production.

From Zylidac Bio LLC 22 Oct 2026

Are shared fryers really off-limits for people with celiac disease?

A study finds most French fries and tortilla chips from shared fryers contain low gluten levels, suggesting revised dietary advice for celiac disease is needed.

22 Oct 2026

BGI Genomics smarter stool testing detects colorectal cancer across Latin America

BGI Genomics' COLOTECT® addresses colorectal cancer in LATAM through innovative non-invasive screening, enhancing early detection and treatment efficiency.

From BGI Genomics 22 Oct 2026

INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar

INmune Bio Inc. (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

From INmune Bio 22 Oct 2026